ONCS - ONCS STOCK NEWS

OncoSec Medical Incorporated (NASDAQ:ONCS) has appointed Bridget O'Keeffe, Ph.D., as Vice President of Clinical Development, effective February 18, 2021. Dr. O'Keeffe brings over 15 years of biotech experience, previously serving as Senior Director of Clinical Development at Nektar Therapeutics. Her roles included leading a global Phase 3 study in renal cell carcinoma. OncoSec's lead product, TAVO™, is under development for cancer treatment and has received FDA Orphan Drug and Fast-Track Designations. The company aims to enhance therapeutic options for patients, especially anti-PD-1 non-responders.

OncoSec Medical has strengthened its management team with the appointment of Brian Leuthner as Chief Operating Officer and Joe Smith as Vice President of Business Development. Both executives bring extensive industry experience, which OncoSec aims to leverage for the development of its lead product candidate, TAVO™, alongside strategic partnerships. TAVO™ is a gene therapy technology showing promise in oncology and has received Orphan Drug and Fast-Track Designation from the FDA for metastatic melanoma.

OncoSec Medical Incorporated (NASDAQ: ONCS) has initiated a Phase 1 clinical trial for its COVID-19 vaccine candidate, CORVax12, which uniquely combines a DNA-encoded spike protein with interleukin-12 (IL-12) to enhance immunogenicity. The trial aims to assess safety and immunogenicity among up to 36 healthy volunteers. Preliminary data suggests CORVax12 may elicit strong immune responses and potentially provide dual benefits as an anti-viral and anti-tumor therapy. The study will track responses four weeks apart using the Cliniporator® platform.

OncoSec Medical Incorporated (NASDAQ:ONCS) announced the completion of a public offering of 7,711,284 shares at $5.45 per share, raising approximately $42 million in gross proceeds. The funds will support clinical development, regulatory, and manufacturing efforts for its lead candidate TAVO™ and general corporate purposes. The offering was managed by BTIG, LLC and others. TAVO™ targets various cancers using a unique gene therapy approach, having received Orphan Drug and Fast-Track Designation from the FDA for metastatic melanoma.

OncoSec Medical (NASDAQ: ONCS) announced a public offering of 7,711,284 shares at $5.45 per share, aiming for gross proceeds of approximately $42 million. The offering is expected to close around January 25, 2021, subject to customary conditions. Funds will be allocated to clinical and regulatory activities, research and development, potential acquisitions, and other corporate purposes. The offering is made under an effective shelf registration statement filed with the SEC.

OncoSec Medical (NASDAQ:ONCS) announced plans for an underwritten public offering of common stock, with the size and terms to be determined. The offering is subject to market conditions and is intended to fund clinical and regulatory activities, R&D, potential acquisitions, and other corporate purposes. BTIG, LLC is the book-running manager for this offering. Proceeds will support the development of TAVO™ and other product candidates, which target cancer through innovative immunotherapy approaches.

Sirtex Medical announced an advancement in its collaboration with OncoSec Medical (NASDAQ: ONCS) regarding TAVO™, a lead product candidate for treating advanced melanoma. The update grants Sirtex the option to co-promote TAVO™ in the U.S., particularly for cases resistant to anti-PD-1 therapies. This option is valid for 90 days after OncoSec files a Biologics License Application. TAVO™, which utilizes electroporation for gene delivery, is in pivotal trials. This update strengthens the existing partnership, as Sirtex already holds an equity stake in OncoSec.

OncoSec Medical announced a co-promotion agreement with Sirtex Medical to market its lead product, TAVO, for anti-PD-1 checkpoint refractory metastatic melanoma in the U.S. Under the deal, Sirtex will pay OncoSec $5 million for the option to co-promote, with a potential additional $20 million if exercised. The agreement allows OncoSec to utilize Sirtex's oncology sales force for eight years, sharing marketing costs, and retaining control over pricing and clinical trials. Sirtex aims to leverage its experience and resources to address unmet medical needs in cancer treatment.

OncoSec Medical announced the dosing of the first patient in the OMS-104 Phase 2 trial, evaluating TAVO, a DNA plasmid IL-12 therapy, in combination with OPDIVO (nivolumab) for advanced melanoma. This trial aims to assess if TAVO enhances clinical outcomes compared to nivolumab alone. The trial involves 33 patients and has three phases, focusing on improving operability and long-term disease control by potentially eliminating tumors before surgery. TAVO has previously shown promise, receiving FDA designations for metastatic melanoma treatment.